Approved Hospital Formulary
Add Formweb to your mobile device
Search results for:
brentuximab vedotin
brentuximab vedotin
Brand names: Adcetris
| Form | Strength |
|---|---|
| POWDER FOR INJECTION, INTRAVENOUS | 50 mg |
Last updated: Jan. 9, 2024
- High Alert: CAUTION: See High-Alert Medication Policy
- Antineoplastic HD PPE and Disposal
- Antineoplastic HD Hazardous Drug Safe Handling Policy
- RCRA: Disposal
- RCRA: Management of Pharmaceutical Waste Policy
- Black Box Warning: Progressive Multifocal Leukoencephalopathy (PML)
- Restricted Restricted Medication
This medication is Inpatient Non-formulary and Restricted to Outpatient Use. There is an exception for pediatric patients if use is necessary in the inpatient setting. Inpatient use requires approval by a physician department leader (i.e. Medical Director or Chair, or hospital CMO) collaborating with a pharmacy leader.
See HERE for more information and workflow.
See HERE for additional pharmacy workflow details.